What are first-line options for treatment of stage IV squamous cell carcinoma (SCC) non–small cell lung cancer (NSCLC) in patients with a sensitizing endothelial growth factor receptor (EGFR) mutation?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

For patients with a sensitizing EGFR mutation, first-line options are as follows:

  • Afatinib
  • Erlotinib
  • Gefinitib

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!